MitoRx Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$9.6M
- Investors
-
13
MitoRx Therapeutics General Information
Description
Developer of small molecule therapeutics designed for weight loss with muscle preservation in obesity-related and cardiometabolic conditions. The company is advancing mitochondrial-targeted persulfide modifiers that restore a signaling mechanism identified through population-based studies, with preclinical data demonstrating efficacy against hepatosteatosis, effectiveness as a monotherapy, and enhanced fat loss with lean mass gain when combined with glucagon-like peptide-1 receptor agonists, enabling biopharmaceutical developers and healthcare providers to access a foundational therapeutic modality that tackles underlying cellular dysfunction to potentially improve patient outcomes across a spectrum of metabolic and degenerative disorders.
Contact Information
Website
www.mitorxtherapeutics.comCorporate Office
- 9400 Garsington Road, Harwell
- Oxford Business Park
- Oxford OX4 2HN
- England, United Kingdom
Corporate Office
- 9400 Garsington Road, Harwell
- Oxford Business Park
- Oxford OX4 2HN
- England, United Kingdom
MitoRx Therapeutics Timeline
MitoRx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC | 17-Nov-2025 | $9.6M | Completed | Pre-Clinical Trials | ||
| 5. Early Stage VC | 01-Nov-2024 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 13-Dec-2023 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 04-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 1. University Spin-Out | 01-Jan-2021 | Completed | Pre-Clinical Trials |
MitoRx Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A2 Ordinary | ||||||||
| Early Series A2 | ||||||||
| Early Series A1 | ||||||||
| A2 Ordinary | ||||||||
| A1 Ordinary | ||||||||
| Ordinary | 3,747,194 | $0.000132 | $1.64 | $1.64 | 1x | $1.64 | 29.52% | |
| Ordinary | 2,072,000 | $0.000132 | $0.99 | $0.99 | 1x | $0.99 | 16.32% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MitoRx Therapeutics Comparisons
Industry
Financing
Details
MitoRx Therapeutics Competitors (9)
One of MitoRx Therapeutics’s 9 competitors is Energesis Pharmaceuticals, a Accelerator/Incubator Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Energesis Pharmaceuticals | Accelerator/Incubator Backed | Cambridge, MA | ||||
| Rivus Pharmaceuticals | Venture Capital-Backed | Charlottesville, VA | ||||
| BioAge Labs | Formerly VC-backed | Emeryville, CA | ||||
| Zealand Pharma | Formerly VC-backed | Soborg, Denmark | ||||
| OrsoBio | Venture Capital-Backed | Menlo Park, CA |
MitoRx Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MitoRx Therapeutics Patents
MitoRx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510041-D0 | Compounds | Pending | 23-Jun-2025 | ||
| GB-202510042-D0 | Compounds | Pending | 23-Jun-2025 | ||
| GB-202510043-D0 | Compounds | Pending | 23-Jun-2025 | ||
| GB-202510044-D0 | Compounds | Pending | 23-Jun-2025 | ||
| GB-202510045-D0 | Compounds | Pending | 23-Jun-2025 |
MitoRx Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MitoRx Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oshen Holdings | Family Office | Minority | ||
| Panacea Capital | Venture Capital | Minority | ||
| Empirical Ventures | Venture Capital | Minority | ||
| Future Planet Capital | Venture Capital | Minority | ||
| Oxford Technology Management | Venture Capital | Minority |
MitoRx Therapeutics FAQs
-
When was MitoRx Therapeutics founded?
MitoRx Therapeutics was founded in 2021.
-
Where is MitoRx Therapeutics headquartered?
MitoRx Therapeutics is headquartered in Oxford, United Kingdom.
-
What is the size of MitoRx Therapeutics?
MitoRx Therapeutics has 14 total employees.
-
What industry is MitoRx Therapeutics in?
MitoRx Therapeutics’s primary industry is Biotechnology.
-
Is MitoRx Therapeutics a private or public company?
MitoRx Therapeutics is a Private company.
-
What is the current valuation of MitoRx Therapeutics?
The current valuation of MitoRx Therapeutics is .
-
What is MitoRx Therapeutics’s current revenue?
The current revenue for MitoRx Therapeutics is .
-
How much funding has MitoRx Therapeutics raised over time?
MitoRx Therapeutics has raised $17.5M.
-
Who are MitoRx Therapeutics’s investors?
Oshen Holdings, Panacea Capital, Empirical Ventures, Future Planet Capital, and Oxford Technology Management are 5 of 13 investors who have invested in MitoRx Therapeutics.
-
Who are MitoRx Therapeutics’s competitors?
Energesis Pharmaceuticals, Rivus Pharmaceuticals, BioAge Labs, Zealand Pharma, and OrsoBio are some of the 9 competitors of MitoRx Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
